Who are Pivmecillinam/augmentin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vonoprazan+amoxicillin 14 days, Gentamicin + narrow spectrum betalactam, Vonoprazan+amoxicillin 7 days, Prednisolone and amoxicillin/clavulanate, Azithromycin and amoxicillin, Vonoprazan + amoxicillin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pivmecillinam-augmentin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pivmecillinam/augmentin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pivmecillinam/augmentin (Pivmecillinam/augmentin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic combination. Area: Infectious Disease.

marketed Beta-lactam antibiotic combination Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Pivmecillinam/augmentin (Pivmecillinam/augmentin) — Radboud University Medical Center. Pivmecillinam is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while augmentin (amoxicillin/clavulanic acid) combines a beta-lactam with a beta-lactamase inhibitor to overcome resistance.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pivmecillinam/augmentin TARGET	Pivmecillinam/augmentin	Radboud University Medical Center	marketed	Beta-lactam antibiotic combination	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Vonoprazan+amoxicillin 14 days	Vonoprazan+amoxicillin 14 days	Xijing Hospital of Digestive Diseases	marketed	Potassium-competitive acid blocker + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
Gentamicin + narrow spectrum betalactam	Gentamicin + narrow spectrum betalactam	University Hospital, Akershus	marketed	Aminoglycoside + Beta-lactam antibiotic combination	Bacterial 30S ribosome (gentamicin); Penicillin-binding proteins (beta-lactam)
Vonoprazan+amoxicillin 7 days	Vonoprazan+amoxicillin 7 days	Xijing Hospital of Digestive Diseases	marketed	Potassium-competitive acid blocker + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
Prednisolone and amoxicillin/clavulanate	Prednisolone and amoxicillin/clavulanate	University of Chicago	marketed	Corticosteroid + Beta-lactam antibiotic combination	Glucocorticoid receptor (prednisolone); Bacterial peptidoglycan cross-linking (amoxicillin); Beta-lactamase (clavulanate inhibition)
Azithromycin and amoxicillin	Azithromycin and amoxicillin	University of Alabama at Birmingham	marketed	Macrolide and beta-lactam antibiotic combination	Bacterial 50S ribosomal subunit (azithromycin); bacterial cell wall peptidoglycan (amoxicillin)
Vonoprazan + amoxicillin	Vonoprazan + amoxicillin	The Third Xiangya Hospital of Central South University	marketed	Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic combination class)

Juan A. Arnaiz · 1 drug in this class
National University of Singapore · 1 drug in this class
Population Health Research Institute · 1 drug in this class
Radboud University Medical Center · 1 drug in this class
UPECLIN HC FM Botucatu Unesp · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pivmecillinam/augmentin — Competitive Intelligence Brief. https://druglandscape.com/ci/pivmecillinam-augmentin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing